Key result
PCAT CT attenuation distinguishes CAD stages, peaking in acute MI versus stable CAD and controls.
Why the study?
The study assessed whether pericoronary adipose tissue CT attenuation, as an imaging biomarker of coronary inflammation, could distinguish different stages of coronary artery disease.
Does pericoronary adipose tissue (PCAT) CT attenuation distinguish between different stages of coronary artery disease (acute MI, stable CAD, and no CAD)?
Cross-Sectional (n=180)
Does pericoronary adipose tissue (PCAT) CT attenuation distinguish between different stages of coronary artery disease (acute MI, stable CAD, and no CAD)?
Answers are grounded in this paper and cite their sources.
PCAT CT attenuation serves as a quantitative imaging biomarker of coronary inflammation that can independently distinguish between acute MI, stable CAD, and no CAD.
AIMS: Vascular inflammation inhibits local adipogenesis in pericoronary adipose tissue (PCAT) and this can be detected on coronary computed tomography angiography (CCTA) as an increase in CT attenuation of PCAT surrounding the proximal right coronary artery (RCA). In this cross-sectional study, we assessed the utility of PCAT CT attenuation as an imaging biomarker of coronary inflammation in distinguishing different stages of coronary artery disease (CAD). METHODS AND RESULTS: Sixty patients with acute myocardial infarction (MI) were prospectively recruited to undergo CCTA within 48 h of admission, prior to invasive angiography. These participants were matched to patients with stable CAD (n = 60) and controls with no CAD (n = 60) by age, gender, BMI, risk factors, medications, and CT tube voltage. PCAT attenuation around the proximal RCA was quantified per-patient using semi-automated software. Patients with MI had a higher PCAT attenuation (-82.3 ± 5.5 HU) compared with patients with stable CAD (-90.6 ± 5.7 HU, P < 0.001) and controls (-95.8 ± 6.2 HU, P < 0.001). PCAT attenuation was significantly increased in stable CAD patients over controls (P = 0.01). The association of PCAT attenuation with stage of CAD was independent of age, gender, cardiovascular risk factors, epicardial adipose tissue volume, and CCTA-derived quantitative plaque burden. No interaction was observed for clinical presentation (MI vs. stable CAD) and plaque burden on PCAT attenuation. CONCLUSION: PCAT CT attenuation as a quantitative measure of global coronary inflammation independently distinguishes patients with MI vs. stable CAD vs. no CAD. Future studies should assess whether this imaging biomarker can track patient responses to therapies in different stages of CAD.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2020) conducted a cross-sectional in Coronary artery disease (n=180). Pericoronary adipose tissue (PCAT) CT attenuation vs. Stable CAD and no CAD controls was evaluated on PCAT CT attenuation around the proximal RCA (p=<0.001). Pericoronary adipose tissue CT attenuation independently distinguished stages of coronary artery disease, being highest in acute MI versus stable CAD and controls.
Synapse has enriched 10 related papers. Consider them for comparative context: